Detection of cytokeratin 19 mRNA and CYFRA 21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer

International Journal of Biological Markers

Volumn 23, Issue 4, 2008, Pages 238-243

  Marrakchi, Raja ^a   Ouerhani, S ^a   Benammar, S ^c   Rouissi, K ^a   Bouhaha, R ^a   Bougatef, K ^a   Messai, Y ^a   Khadimallah, I ^a   Rahal, K ^b   Ammar Elgaaied, A Ben ^a  

^a UNIVERSITY OF TUNIS   (Tunisia)

^b SALAH AZAIEZ INSTITUTE   (Tunisia)

^c HABIB THAMEUR HOSPITAL   (Tunisia)

Author keywords

Breast cancer; CYFRA 21 1; Cytokeratin; Metastasis

Indexed keywords

ACID PROTEIN; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; MESSENGER RNA; MOLECULAR MARKER; MONOCLONAL ANTIBODY; TUMOR MARKER; ANTIGEN CYFRA21.1; KERATIN; TUMOR ANTIGEN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER STAGING; CELL MIGRATION; CONTROLLED STUDY; CYTOSKELETON; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MICROMETASTASIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DIFFERENTIATION; TUMOR DIFFERENTIATION; TUNISIA; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ADULT; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-19; KERATINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUNISIA;

EID: 65349154656     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.4229     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6.
2. Charef-Hamza S, Trimeche M, Ziadi M, Amara K, Gaddas N, Mokni M. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer. Cancer Lett 2005; 224: 185-91.
3. Sundström BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 1994; 9: 102-8.
4. Stieber P, Dienemann H, Hasholzner U, et al. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 1994; 9: 82-8.
5. Doweck I, Barak M, Greenberg E, et al. CYFRA 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1995; 121: 177-81.
6. Nakata B, Chung YS, Kato Y, et al. Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 1996; 73: 1529-32.
7. Hasholzner U, Baumgartner L, Stieber P, Meier W, Hofmann K, Fateh-Moghadam A. Significance of the tumor markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res 1994; 14: 2743-6.
8. Nakata B, Ogawa Y, Ishikawa T, et al. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 2000; 89: 1285-90.
9. Theyer G, Durer A, Theyer U, et al. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Prostate 1999, 41: 71-7.
10. Giovanella L, Ceriani L, Ghelfo A, Maffioli M. Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. Int J Biol Markers 2008; 23: 54-7.
11. Fernandez-Gomez J, Rodríguez-Martínez JJ, Barmadah SE, et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 2007; 51: 1267-74.
12. Xenidis N, Vlachonikolis I, Mavroudis D, et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003; 14: 849-55.
13. Cote RJ, Rosen PP, Lesser ML, et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9: 1749-56.
14. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-8.
15. Schoenfeld A, Kruger KH, Gomm J, et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997; 33: 854-61.
16. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-82.
17. Krismann M, Todt B, Schroder J, et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 2769-75.
18. Berois N, Varangot M, Osinaga E, et al. Detection of rare human breast cancer cells: Comparison of an immunomagnetic separation method with immunochemistry and RTPCR. Anticancer Res 1997; 17: 2639-46.
19. Peck K, Sher YP, Shih JY, et al. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res 1998; 58: 2761-5.
20. Ko Y, Grunewald E, Totzke G, et al. High percentage of false-positive results of cytokeratin 19 RT-PCR in blood: a model for the analysis of illegitimate gene expression. Oncology 2001; 59: 81-8.
21. Molina R, Agusti C, Filella X, et al. Study of a new tumor marker, CYFRA 21-1, in malignant and non malignant diseases. Tumour Biol 1994; 15: 318-25.
22. Rodriguez CA, Cruz JJ, Martin T, Gomez A, Olaverri A, Hernandez M. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 2002; 95: 670-1.
23. Brotherick I, Robson CN, Browell DA, et al. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 1998; 32: 301-8.
24. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragments of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61-6.
25. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer 2004; 91: 873-8.
26. Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med 2002; 40: 298-303.